A NEW ERA: 
DEEP YET NON-INVASIVE 
BRAIN STIMULATION

The patented breakthrough technology of Brainsway™ launches a new era in the treatment of brain disorders. Brainsway offers a non-invasive yet highly effective treatment that activates deep brain structures. This is achieved using directed electromagnetic fields which generate excitation or inhibition of neurons deep inside the brain. The technology has been enthusiastically embraced by the international academic community, with over 60 clinical studies in leading institutions worldwide.

Unique Patented Coil Structure

Brainsway's Deep TMS (Deep Transcranial Magnetic Stimulation) technology is based on the H Coil, featuring a novel patented structure which maximizes electrical stimulation of deep brain regions. Unique features of the coil design include:

- Coil elements tangential to the head and close to target brain regions
- Flexible base suited to head shape
- Convergence of numerous electric pulses from various directions
- Coil elements parallel to target bundles
- Location of return paths of electrical impulses remote from target area

Brainsway technology is based on a patent registered by the U.S. National Institutes of Health (NIH). Brainsway has an exclusive license from the NIH for both the patent and the technology.
Proven Efficacy

Studies show that stimulation of deeper (ventral) PFC structures significantly enhances antidepressant effects. The FDA has cleared Brainsway’s Deep TMS technology for treatment of a wide range of Depression patients, from mild to severe cases, who did not benefit from antidepressants in the current depressive episode. The indication is based on a 16-week double blind placebo controlled study enrolling over 230 subjects and showing a profound decline in HDRS-21, and significant remission and response rates.

Response and Remission Rates at Week 5

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Response Rates (P=0.0138)</th>
<th>Remission Rates (P=0.0051)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deep TMS</td>
<td>38.4%</td>
<td>32.6%</td>
</tr>
<tr>
<td>Sham</td>
<td>21.3%</td>
<td>14.6%</td>
</tr>
</tbody>
</table>

- Remission = HDRS-21 Score < 10
- Response = Improvement of at least 50% from baseline

HDTRS-21 Score Over Time

- Treatment group
  - Deep TMS (N=89)
  - Sham (N=92)

Slope (adjusted) of Change Deep TMS = -6.39 points
Slope (adjusted) of Change Sham = -3.28 points
P-value of Difference = 0.0080

1 The Deep TMS depression treatment and surface TMS depression treatment were not compared in head to head studies.
2 The Brainsway Deep TMS System is indicated by the FDA for the treatment of depressive episodes in adult patients suffering from Major Depressive Disorder, who failed to achieve satisfactory improvement from previous anti-depressant medication treatment in the current episode. FDA 510(k) No. K122288